Swanson Reed News

ResMed’s R&D Investment Has Increased Profits By 13%

November 7th, 2017

ResMed provide a range of medical devices that help to diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease and other chronic diseases. For the first quarter of the financial year, ResMed’s profits grew by 13 percent to $US523.7 million. Chief executive Mick Farrell said that continuous product innovation was helping the company to increase its market share. He stated that ResMed continues to “Pioneer products, services and solutions that improve patient outcomes, create efficiencies for our homecare providers, […]

Read More

Australian R&D Spend is Decreasing for the First Time in Decades

September 26th, 2017

The Australian Bureau of Statistics has found that company expenditure on research and development has declined by 12 percent between 2013-14 and 2015-16. This is close to dipping below 1 percent of GDP, or $16.6 billion. Although manufacturing remained the largest spender of R&D, R&D spending in the mining and manufacturing industries was down. Mining decreased by 34 percent ($954 million) while manufacturing was down 19 percent ($936 million). The R&D tax incentive is expected to cost the government around $3.5 […]

Read More

R&D securing your company’s competitive position in the market

September 21st, 2017

An exciting time lies ahead for the research and development (R&D) industry as Sydney will soon be home to BT’s new global cyber security R&D centre, facilitating 172 additional skilled jobs over the next five years. The R&D hub is an expansion to BT’s existing Security Operation Centre (SOC) in Berry Street and will be the company’s first cyber R&D facility outside of the United Kingdom. The NSW Government has provided a $1.67 million grant to BT in support of the […]

Read More

Pharma stocks to invest in based on R&D spending levels

August 28th, 2017

Continued research and development (R&D) is a must in the pharmaceutical industry as even the biggest blockbuster drugs eventually lose patent exclusivity or face new and improved competition. However throwing money into R&D alone doesn’t guarantee success, it is vital to also make smart investments into companies which are successfully incorporating R&D into their business activities. The following five pharma stocks are recommended for investors to own based on R&D spending levels. Merck Merck invested $6.8 billion into R&D in […]

Read More

Bryce Steele
Principal, Melbourne
Tel: (03) 9018 5778
Mob: 0435 713 493
Tom Parkhouse
Principal, Sydney
Tel: (02) 8006 0559
Mob: 0411 718 565
Andy Nguyen
Principal, Brisbane
Tel: (07) 3221 1499
Mob: 0407 750 249
Kieu McKellar
Manager, Adelaide
Tel: (08) 8121 7850
Mob: 0435 713 493
David Greatwich
Principal, Perth
Tel: (08) 9340 3745
Mob: 0468 386 250
Sarah Guan
Manager, Hobart
Tel: (03) 9018 5778
Mob: 0401 262 591



Email this job